ArticleFrontiers in molecular biosciences2025
Identification of
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune response to DNA and RNA: structural insights, molecular mechanisms, and therapeutic targeting.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumor staging is critical for guiding therapeutic decisions and determining prognosis in liver hepatocellular carcinoma (LIHC). This study aimed to identify potential tissue biomarkers intrinsically linked to disease stage to enhance our understanding of LIHC biology. Methods: Transcriptome and clinical data from LIHC patients were obtained from The Cancer Genome Atlas (TCGA) database. Differential expression analysis was conducted using the "limma" package. Weighted gene co-expression network analysis (WGCNA) was used to identify the gene module most strongly associated with LIHC and to extract hub genes. The hub genes then underwent differential expression, prognostic, and clinical staging analyses, immunohistochemical validation, and multivariable Cox regression analysis. Results: This analysis included data from 373 LIHC tumors and 50 solid tissue normal samples obtained from the TCGA database. Differential expression analysis identified 319 upregulated and 853 downregulated genes in LIHC tumors compared to these normal samples. An enrichment analysis highlighted key pathways, including cell cycle, DNA replication, and base excision repair. Three independent validation datasets confirmed 18 downregulated and 7 upregulated genes. Among them, Conclusion: Our results identified
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.